Finance

Beta
Lists
002390:SHE
Guizhou Xinbang Pharmaceutical Co Ltd
CNÂ¥2.96
+0.34%
(+0.0100) 1D
Jun 5, 3:04:48 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002390...
Open
CNÂ¥2.94
High
CNÂ¥3.01
Low
CNÂ¥2.94
Mkt. cap
5.75B
Avg. vol.
26.00M
Volume
16.44M
Dividend
3.04%
Quarterly dividend
CNÂ¥0.02
Ex-dividend date
May 21, 2026
P/E ratio
42.43
52-wk high
CNÂ¥4.15
52-wk low
CNÂ¥2.93
EPS
CNÂ¥0.07
Shares outstanding
1.94B
No. of employees
5K
Open
CNÂ¥2.94
High
CNÂ¥3.01
Low
CNÂ¥2.94
Mkt. cap
5.75B
Avg. vol.
26.00M
Volume
16.44M
Dividend
3.04%
Quarterly dividend
CNÂ¥0.02
Ex-dividend date
May 21, 2026
P/E ratio
42.43
52-wk high
CNÂ¥4.15
52-wk low
CNÂ¥2.93
EPS
CNÂ¥0.07
Shares outstanding
1.94B
No. of employees
5K
News stories
From sources across the web
About Guizhou Xinbang Pharmaceutical Co Ltd
CEO-
Employees4.7K
FoundedJan 27, 1995
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.40B
1.42B
1.35B
1.26B
Cost of goods sold
1.14B
1.17B
1.12B
1.06B
Cost of revenue
1.14B
1.17B
1.12B
1.06B
Research and development expenses
2.30M
1.28M
1.50M
1.95M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
147.14M
151.56M
153.22M
121.62M
Operating expense
155.46M
175.60M
181.58M
127.31M
Total operating expenses
1.30B
1.34B
1.30B
1.19B
Operating income
104.68M
76.59M
54.46M
77.38M
Other non operating income
-4.08M
-6.48M
-56.24M
259.61K
EBT including unusual items
98.17M
65.97M
4.74M
76.27M
EBT excluding unusual items
98.24M
65.91M
16.58M
76.18M
Income tax expense
9.58M
7.64M
13.72M
11.71M
Effective tax rate
9.76%
11.57%
289.59%
15.36%
Other operating expenses
5.19M
17.06M
10.40M
5.92M
Net income
65.95M
45.13M
-32.04M
48.66M
Net profit margin
4.70%
3.18%
-2.37%
3.85%
Earnings per share
-
-
-
-
Interest and investment income
2.31M
1.56M
20.59M
1.86M
Interest expense
-4.66M
-5.76M
-2.25M
-3.32M
Net interest expenses
-2.35M
-4.20M
18.35M
-1.45M
Depreciation and amortization charges
-
-
-
-
EBITDA
153.37M
128.65M
102.75M
125.66M
Gain or loss from assets sale
-95.70K
95.70K
3.48M
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more